Inflammation and asthma have both been reported in some children with autism spectrum disorder (ASD). To further assess this connection, peripheral immune cells isolated from young children with ASD and typically developing (TD) controls and the production of cytokines IL-17, -13, and -4 assessed following ex vivo mitogen stimulation. Notably, IL-17 production was significantly higher following stimulation in ASD children compared to controls. Moreover, IL-17 was increased in ASD children with co-morbid asthma compared to controls with the same condition. In conclusion, children with ASD exhibited a differential response to T cell stimulation with elevated IL-17 production compared to controls.
Introduction
Autism spectrum disorder (ASD) is a group of heterogeneous, behaviorally defined disorders whereby affected individuals are characterized by impairments in social interaction, verbal and nonverbal communication, often with stereotypical behaviors and restricted interests. The current prevalence of ASD is 1:68 children, with 1:42 affecting boys (Corcoran et al., 2015; Magalhães et al., 2009 ). There are currently no biological markers common to all individuals with ASD. The causes of ASD have yet to be discovered, and it has been suggested that ASD comprises of a combination of multiple etiologies, including gene X environment interaction (Croen et al., 2005; Lawler, 2008; Lyall et al., 2013; Money et al., 1971) . A growing body of research has demonstrated that the immune response may be a contributing factor in the etiology and/or ontogeny of ASD (Ashwood et al., 2006; Careaga et al., 2010; Comi et al., 1999; Croen et al., 2005; Lawler, 2008; Lyall et al., 2013 Lyall et al., , 2015 Menage et al., 1992; Money et al., 1971; Renzoni et al., 1995) . Previous findings indicate that some children with ASD have dysregulated immune responses such as increased natural killer cell activity (Enstrom et al., 2009) , the presence of autoantibodies directed against brain proteins (Goines et al., 2011a) , and altered cytokine profiles (Ashwood et al., 2010a (Ashwood et al., , 2011a Corcoran et al., 2015) .
Studies have also suggested that several co-morbidities might be associated with autism including immune-mediated disorders such as asthma, allergy and skin disorders such as atopic dermatitis and eczema (Lawler, 2008; Magalhães et al., 2009; Sacco et al., 2012) . In addition, there is an increased prevalence of immune-mediated disorders in family members of children with ASD (Ashwood et al., 2006; Careaga et al., 2010; Comi et al., 1999; Croen et al., 2005; Lyall et al., 2013; Money et al., 1971) . However, there are conflicting reports among the research findings regarding the prevalence of clinically relevant immune-mediated conditions and whether they are an accurate or only indicate immune dysregulation in ASD (Enstrom et al., 2009; Lyall et al., 2013; Menage et al., 1992; Renzoni et al., 1995) . For instance, reported levels of IgE antibodies, which play a key role in the allergic immune response, are not consistently different between ASD and typically developing (TD) controls (Bakkaloglu et al., 2008; Goines et al., 2011a; Heuer et al., 2008) and makes for a poor biomarker for immune dysregulation in ASD. Thus, in light of the current ambiguity in reported allergic conditions in ASD (Croen et al., 2005; Lyall et al., 2013 Lyall et al., , 2015 it is of great interest to better understand the relationship between the immune anomalies noted in some children with ASD and the presence of the co-morbid conditions such as asthma, allergy, and eczema. It is Journal of Neuroimmunology 286 (2015) 33-41 
